Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients

ABSTRACT: The variability and unpredictability of drug efficacy in ulcerative colitis (UC) patients, including tofacitinib, an oral JAK1 and JAK3 inhibitor, remains a perplexing reality. Here, we use single-cell RNA sequencing (scRNA-seq) analysis of intestinal cells from UC patients receiving tofacitinib to identify the cellular subsets and genes involved in the response and/or resistance to tofacitinib.

ORGANISM(S): Homo sapiens

PROVIDER: GSE253006 | GEO | 2025/05/19

REPOSITORIES: GEO